BIOMAT Database Logo BIOMAT Database Logo

[Cycloergometric evaluation of the effects of verapamil in chronic coronary insufficiency]. 1977

R S Meneghelo, and R Duprat, and M Batlouni, and C A Severino, and D Armaganijan, and H M Magalhães, and J Feher

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010919 Placebos Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. Sham Treatment
D001835 Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms. Body Weights,Weight, Body,Weights, Body
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D003327 Coronary Disease An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels. Coronary Heart Disease,Coronary Diseases,Coronary Heart Diseases,Disease, Coronary,Disease, Coronary Heart,Diseases, Coronary,Diseases, Coronary Heart,Heart Disease, Coronary,Heart Diseases, Coronary
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D004562 Electrocardiography Recording of the moment-to-moment electromotive forces of the HEART as projected onto various sites on the body's surface, delineated as a scalar function of time. The recording is monitored by a tracing on slow moving chart paper or by observing it on a cardioscope, which is a CATHODE RAY TUBE DISPLAY. 12-Lead ECG,12-Lead EKG,12-Lead Electrocardiography,Cardiography,ECG,EKG,Electrocardiogram,Electrocardiograph,12 Lead ECG,12 Lead EKG,12 Lead Electrocardiography,12-Lead ECGs,12-Lead EKGs,12-Lead Electrocardiographies,Cardiographies,ECG, 12-Lead,EKG, 12-Lead,Electrocardiograms,Electrocardiographies, 12-Lead,Electrocardiographs,Electrocardiography, 12-Lead

Related Publications

R S Meneghelo, and R Duprat, and M Batlouni, and C A Severino, and D Armaganijan, and H M Magalhães, and J Feher
[Cycloergometric evaluation of propatylnitrate in chronic coronary insufficiency].
January 1980, Arquivos brasileiros de cardiologia,
R S Meneghelo, and R Duprat, and M Batlouni, and C A Severino, and D Armaganijan, and H M Magalhães, and J Feher
[Cycloergometric evaluation of fendiline in chronic coronary insufficiency].
September 1979, Arquivos brasileiros de cardiologia,
R S Meneghelo, and R Duprat, and M Batlouni, and C A Severino, and D Armaganijan, and H M Magalhães, and J Feher
[Cycloergometric evaluation of the continuous use of verapamil 360 mg/per day in chronic coronary insufficiency].
February 1977, Arquivos brasileiros de cardiologia,
R S Meneghelo, and R Duprat, and M Batlouni, and C A Severino, and D Armaganijan, and H M Magalhães, and J Feher
[Comparative study of the medium term use of verapamil and perhexiline in the treatment of chronic coronary insufficiency. Clinical and cycloergometric evaluation].
February 1978, Arquivos brasileiros de cardiologia,
R S Meneghelo, and R Duprat, and M Batlouni, and C A Severino, and D Armaganijan, and H M Magalhães, and J Feher
[Initial experience. Comparative study of verapamil and nifedipine in the treatment of coronary insufficiency. Evaluation by a cycloergometric test].
February 1978, Arquivos brasileiros de cardiologia,
R S Meneghelo, and R Duprat, and M Batlouni, and C A Severino, and D Armaganijan, and H M Magalhães, and J Feher
[Effects of verapamil on the cycloergometric test in patients of coronary artery disease].
February 1977, Arquivos brasileiros de cardiologia,
R S Meneghelo, and R Duprat, and M Batlouni, and C A Severino, and D Armaganijan, and H M Magalhães, and J Feher
[The cycloergometric exercise test in the radiotelemetric diagnosis of coronary insufficiency].
June 1979, Minerva medica,
R S Meneghelo, and R Duprat, and M Batlouni, and C A Severino, and D Armaganijan, and H M Magalhães, and J Feher
[Hemodynamic and coronary effects of intravenous verapamil in coronary insufficiency].
June 1981, Archives des maladies du coeur et des vaisseaux,
R S Meneghelo, and R Duprat, and M Batlouni, and C A Severino, and D Armaganijan, and H M Magalhães, and J Feher
[Clinical and cycloergometric evaluation of verapamil in the therapeutic of angina pectoris].
February 1977, Arquivos brasileiros de cardiologia,
R S Meneghelo, and R Duprat, and M Batlouni, and C A Severino, and D Armaganijan, and H M Magalhães, and J Feher
[Hemodynamic effects of verapamil in patients with coronary insufficiency].
February 1978, Arquivos brasileiros de cardiologia,
Copied contents to your clipboard!